Why the study?
To measure targeted blood protein changes using a previously developed 21-protein panel in an ultraendurance cyclist competing in RAAM.
Does ultraendurance cycling alter proteomic markers of non-functional overreaching in an athlete?
Does ultraendurance cycling alter proteomic markers of non-functional overreaching in an athlete?
Ultraendurance cycling induces non-functional overreaching characterized by significant increases in acute-phase immune proteins like complement C7 and serum amyloid A-4, which may serve as biomarkers for overtraining.
Single-athlete proteomics data should not change overtraining monitoring; leaves open validation in larger cohorts.
In a previous study, proteomics procedures identified blood proteins as potential overreaching and overtraining biomarkers, and a targeted proteomics panel of 21 proteins was developed. PURPOSE: To measure targeted blood protein changes in an ultraendurance cyclist competing in RAAM. METHODS: The athlete underwent testing 4-week pre-RAAM and 4-day post-RAAM to determine body composition and aerobic capacity. During RAAM training distress score (TDS) and body mass were measured daily. Power output and heart rate (HR) were measured during cycling. Blood sampling for proteomic analysis occurred 4 weeks, 24, and 2 h before the start, twice per day of the race, and after 1 and 4 days recovery. RESULTS: and 192 bpm vs. 181 bpm). Body composition did not change. The change in blood proteins was calculated using pre-race samples and samples collected on days 8, 9, and recovery day 1. The blood proteins with the largest increase were complement component C7 (359%), complement C4-B (231%), serum amyloid A-4 protein (210%), inter-alpha-trypsin inhibitor heavy chain H4 (191%), and alpha-1-antitrypsin (188%). CONCLUSION: The RAAM athlete exhibited non-functional overreaching symptoms including increased training distress and decreased work capacity. Proteomic analysis indicated large increases for immune-related proteins involved with complement activation and the acute phase response, which could be useful biomarkers for non-functional overreaching.
No takes yet. Share an insight, caveat, or question.
Merritt et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: